We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Troubles continue for Neurocrine Biosciences in the wake of a regulatory delay of the insomnia drug indiplon as the company announced it is eliminating its sales staff.